Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 25 02:21PM ET
3.09
Dollar change
-0.09
Percentage change
-2.83
%
IndexRUT P/E- EPS (ttm)-0.62 Insider Own7.44% Shs Outstand150.29M Perf Week-4.19%
Market Cap465.51M Forward P/E- EPS next Y-0.01 Insider Trans0.00% Shs Float139.45M Perf Month-10.95%
Income-80.95M PEG- EPS next Q-0.04 Inst Own72.67% Short Float21.54% Perf Quarter4.75%
Sales132.10M P/S3.52 EPS this Y85.89% Inst Trans6.71% Short Ratio14.16 Perf Half Y77.59%
Book/sh-0.22 P/B- EPS next Y87.44% ROA-36.90% Short Interest30.04M Perf Year155.37%
Cash/sh0.47 P/C6.51 EPS next 5Y47.50% ROE-2408.88% 52W Range0.50 - 3.93 Perf YTD81.76%
Dividend Est.- P/FCF- EPS past 5Y20.01% ROI-56.90% 52W High-21.37% Beta1.80
Dividend TTM- Quick Ratio1.90 Sales past 5Y17.85% Gross Margin57.08% 52W Low518.00% ATR (14)0.23
Dividend Ex-Date- Current Ratio2.47 EPS Y/Y TTM54.94% Oper. Margin-62.34% RSI (14)41.39 Volatility8.30% 6.75%
Employees126 Debt/Eq- Sales Y/Y TTM16.05% Profit Margin-61.28% Recom1.20 Target Price6.80
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q92.39% Payout- Rel Volume0.47 Prev Close3.18
Sales Surprise5.13% EPS Surprise73.15% Sales Q/Q17.07% EarningsMay 07 BMO Avg Volume2.12M Price3.09
SMA20-12.15% SMA50-0.88% SMA20046.35% Trades Volume763,369 Change-2.83%
Date Action Analyst Rating Change Price Target Change
Jun-13-24Initiated Rodman & Renshaw Buy $7
Apr-23-24Initiated CapitalOne Overweight $6
Mar-13-24Reiterated Needham Buy $4 → $5
May-27-20Initiated Guggenheim Buy $24
Feb-20-20Reiterated Needham Buy $50 → $48
Jan-16-19Reiterated Needham Buy $66 → $64
Apr-05-18Initiated Evercore ISI Outperform $56
Mar-19-18Reiterated Mizuho Buy $28 → $35
Mar-01-18Reiterated Needham Buy $28 → $30
Jan-03-18Initiated Leerink Partners Outperform $22
May-29-24 08:05AM
May-21-24 12:00PM
May-08-24 12:30PM
03:10AM
May-07-24 12:54PM
09:34AM Loading…
09:34AM
09:30AM
09:05AM
08:06AM
08:00AM
Apr-30-24 10:01AM
Apr-24-24 08:00AM
Apr-11-24 04:05PM
Mar-28-24 04:05PM
Mar-13-24 09:19AM
07:04AM Loading…
07:04AM
Mar-12-24 06:00PM
05:33PM
04:34PM
04:05PM
Mar-07-24 09:15AM
Feb-28-24 08:00AM
Feb-23-24 11:56AM
Feb-06-24 12:00PM
Jan-25-24 06:44AM
Jan-24-24 01:47PM
Jan-23-24 08:00PM
Jan-15-24 04:51PM
09:55AM
Jan-07-24 05:00PM
12:23PM Loading…
Dec-10-23 12:23PM
Dec-06-23 11:55AM
Nov-28-23 07:33PM
Nov-15-23 10:17AM
08:51AM
08:46AM
Nov-14-23 06:00PM
04:17PM
04:05PM
Nov-07-23 04:05PM
Aug-24-23 09:29AM
Aug-15-23 01:30PM
12:48PM
09:47AM
Aug-14-23 04:29PM
04:05PM
Aug-07-23 04:05PM
10:50AM
Jul-26-23 01:30PM
Jul-24-23 09:02AM
09:00AM
Jun-23-23 04:05PM
Jun-12-23 09:00AM
May-11-23 05:15PM
04:12PM
04:01PM
May-05-23 12:28PM
Apr-20-23 11:45AM
09:00AM
Apr-17-23 04:05PM
Apr-06-23 03:42PM
02:01PM
Apr-03-23 09:00AM
Mar-27-23 07:12AM
Mar-24-23 06:43AM
Mar-23-23 09:28PM
05:35PM
04:05PM
Mar-13-23 09:00AM
Mar-10-23 04:05PM
Mar-06-23 09:00AM
Feb-27-23 04:30PM
Feb-22-23 09:00AM
Jan-30-23 05:54AM
Jan-09-23 08:30AM
Dec-29-22 09:45AM
09:00AM
Dec-28-22 12:32PM
Dec-20-22 03:41PM
Nov-21-22 04:05PM
Nov-15-22 10:14PM
Nov-10-22 05:44AM
Nov-09-22 01:15PM
Nov-08-22 06:25PM
04:05PM
Nov-04-22 11:48AM
Nov-01-22 04:05PM
Sep-26-22 09:45AM
Sep-23-22 09:19AM
07:30AM
Sep-19-22 06:42AM
Sep-16-22 02:49PM
Sep-12-22 07:37AM
Aug-23-22 12:00PM
Aug-15-22 09:55AM
Aug-09-22 02:10PM
09:15AM
08:01AM
08:00AM
Aug-02-22 04:05PM
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Forbes William PEVP, Chief Development OfficerNov 17 '23Buy1.0925,00027,25079,000Nov 21 12:19 PM
Collard Craig AChief Executive OfficerNov 16 '23Buy0.92150,000137,970186,496Nov 17 12:37 PM
Duarte IraEVP, Chief Financial OfficerNov 16 '23Buy0.8985,00075,59985,000Nov 17 12:36 PM
Forbes William PEVP, Chief Development OfficerNov 16 '23Buy0.9450,00046,99554,000Nov 20 10:07 AM
Morgan AdamDirectorJul 21 '23Buy1.372,486,7443,406,8396,986,744Jul 25 04:22 PM